Aqualung Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $3.25M

  • Investors
  • 10

Aqualung Therapeutics General Information

Description

Developer of an immune-focused biologic platform designed for serious inflammatory disorders. The company strategies include the deployment of a humanized monoclonal antibody that targets a novel inflammatory mediator eNAMPT, enabling medical practitioners to address the unmet need for novel, effective therapies for VILI, idiopathic pulmonary fibrosis and pulmonary hypertension in patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6080 North Pinchot Road
  • Tucson, AZ 85750
  • United States
+1 (312)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 6080 North Pinchot Road
  • Tucson, AZ 85750
  • United States
+1 (312)

Aqualung Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aqualung Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series A) 04-Apr-2023 $3.25M Completed Clinical Trials - Phase 1
8. Grant 20-Aug-2022 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A) 27-Jun-2022 Completed Clinical Trials - Phase 1
6. Grant 01-Jan-2020 Completed Pre-Clinical Trials
5. Grant 01-Jun-2020 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 13-Jan-2020 Cancelled Pre-Clinical Trials
3. Seed Round 11-Oct-2019 Completed Pre-Clinical Trials
2. Grant 01-Jan-2019 $2.15M Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2018 Completed Pre-Clinical Trials
To view Aqualung Therapeutics’s complete valuation and funding history, request access »

Aqualung Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Aqualung Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Aqualung Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immune-focused biologic platform designed for serious inflammatory disorders. The company strategies inc
Drug Discovery
Tucson, AZ
5 As of 2024

Brighton, United Kingdom
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aqualung Therapeutics Competitors (29)

One of Aqualung Therapeutics’s 29 competitors is Enterprise Therapeutics, a Venture Capital-Backed company based in Brighton, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom
hVIVO Formerly VC-backed London, United Kingdom
Windtree Therapeutics Corporate Backed or Acquired Warrington, PA
Attune Pharmaceuticals Venture Capital-Backed New York, NY
Codiak BioSciences Formerly VC-backed Cambridge, MA
You’re viewing 5 of 29 competitors. Get the full list »

Aqualung Therapeutics Patents

Aqualung Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11466099-B2 Anti-human nicotinamide phosphoribosyltransferase (nampt) antibodies Active 07-Aug-2019
US-20220056152-A1 Anti-human nicotinamide phosphoribosyltransferase (nampt) antibodies Active 07-Aug-2019
EP-4010368-A1 Anti-nampt antibodies and uses thereof Pending 07-Aug-2019
JP-2022543658-A Anti-nampt antibody and use thereof Pending 07-Aug-2019
AU-2020325315-A1 Anti-nampt antibodies and uses thereof Pending 07-Aug-2019 C07K16/40
To view Aqualung Therapeutics’s complete patent history, request access »

Aqualung Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aqualung Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
7G Bioventures Venture Capital Minority
Arizona State University University Minority
Florida Opportunity Fund Venture Capital Minority
National Institute of Diabetes and Digestive and Kidney Diseases Government
Ironwood Investment Management Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Aqualung Therapeutics FAQs

  • When was Aqualung Therapeutics founded?

    Aqualung Therapeutics was founded in 2010.

  • Where is Aqualung Therapeutics headquartered?

    Aqualung Therapeutics is headquartered in Tucson, AZ.

  • What is the size of Aqualung Therapeutics?

    Aqualung Therapeutics has 5 total employees.

  • What industry is Aqualung Therapeutics in?

    Aqualung Therapeutics’s primary industry is Drug Discovery.

  • Is Aqualung Therapeutics a private or public company?

    Aqualung Therapeutics is a Private company.

  • What is the current valuation of Aqualung Therapeutics?

    The current valuation of Aqualung Therapeutics is .

  • What is Aqualung Therapeutics’s current revenue?

    The current revenue for Aqualung Therapeutics is .

  • How much funding has Aqualung Therapeutics raised over time?

    Aqualung Therapeutics has raised $9.6M.

  • Who are Aqualung Therapeutics’s investors?

    7G Bioventures, Arizona State University, Florida Opportunity Fund, National Institute of Diabetes and Digestive and Kidney Diseases, and Ironwood Investment Management are 5 of 10 investors who have invested in Aqualung Therapeutics.

  • Who are Aqualung Therapeutics’s competitors?

    Enterprise Therapeutics, hVIVO, Windtree Therapeutics, Attune Pharmaceuticals, and Codiak BioSciences are some of the 29 competitors of Aqualung Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »